Earlier studies of our group had discovered the FANCD2 mutant 2022-5C>T in every single BC-CML patient, and by employing whole-exome sequencing, they had narrowed their search for a “Common and specific biomarker for BC-CML” to only those genes that were mutated in all patients with BC-CML and not in any patients with CP-CML or healthy controls [20]. This evidence concerns the gene FANCD2 and chronic myelogenous leukemia, BCR-ABL1 positive.